Precision Medicine in Oncology®

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Targeting Dormant Cancer Cells

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Deirdre Cohen, from NYU Medical Oncology Associates, Addresses the Role of the Hedgehog Pathway

Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays

The treatment of Gaucher disease is poised to enter a new era as a result of advances in the understanding of the cellular pathways at work in the disorder.

Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors

With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.

Dr. Harold Burstein, from the Dana-Farber Cancer Institute, Discusses Pathological Complete Response

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

Dr. Emily Chan, from Vanderbilt-Ingram Cancer Center, Discusses the VEGF-Trap Agent Aflibercept

Dr. Deirdre Cohen, NYU Medical Oncology Associates, Discusses Hedgehog Pathway Inhibition

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.

Mustard derivatives' potent lethality has ensured its descendents a place in oncology treatment regimens today, even amid advances in targeted therapies.

p53 coordinates a number of antiproliferative programs in response to multiple forms of stress, including low oxygen, depletion of ribonucleotides, hyperactivation of growth signaling, and many forms of DNA damage.

As its moniker As its moniker "guardian of the genome" suggests, p53 has become recognized as one of the most important cancer-related molecules in the cell.

The John Theurer Cancer Center (JTCC), at Hackensack University Medical Center in New Jersey, is one of the largest cancer facilities in the US.

Since its discovery, phosphorylation has come to be recognized as a global regulator of cellular activity, and abnormal phosphorylation is implicated in a host of human diseases.

Martin Steffen, MD, PhD, developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

Cancer treatment is moving from a one-size-fits-all approach to personalized medicine, which means matching the right drug with the right tumor characteristics.

Andre Goy, MD, MS, treats lymphoma patients at New Jersey's largest cancer center, Goy, 54, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib.

Although the use of tumor markers to evaluate patients with breast cancer is well established, the nuances involved in such testing are growing along with the emergence of novel assays and fresh research findings.

Established in 1973 as the University of Pennsylvania's Cancer Center and subsequently renamed in 2002, the Abramson Cancer Center is a world leader in research, patient care, and education.